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SinBACKGROUND Classiﬁcation of chronic heart failure (HF) is on the basis of criteria that may not adequately capture
disease heterogeneity. Improved phenotyping may help inform research and therapeutic strategies.
OBJECTIVES This study used cluster analysis to explore clinical phenotypes in chronic HF patients.
METHODS A cluster analysis was performed on 45 baseline clinical variables from 1,619 participants in the HF-ACTION
(Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) study, which evaluated exercise training
versus usual care in chronic systolic HF. An association between identiﬁed clusters and clinical outcomes was assessed
using Cox proportional hazards modeling. Differential associations between clinical outcomes and exercise testing were
examined using interaction testing.
RESULTS Four clusters were identiﬁed (ranging from 248 to 773 patients in each), in which patients varied considerably
among measures of age, sex, race, symptoms, comorbidities, HF etiology, socioeconomic status, quality of life, cardio-
pulmonary exercise testing parameters, and biomarker levels. Differential associations were observed for hospitalization
and mortality risks between and within clusters. Compared with cluster 1, risk of all-cause mortality and/or all-cause
hospitalization ranged from 0.65 (95% conﬁdence interval [95% CI]: 0.54 to 0.78) for cluster 4 to 1.02 (95% CI: 0.87
to 1.19) for cluster 3. However, for all-cause mortality, cluster 3 had a disproportionately lower risk of 0.61 (95% CI: 0.44
to 0.86). Evidence suggested differential effects of exercise treatment on changes in peak oxygen consumption and
clinical outcomes between clusters (p for interaction <0.04).
CONCLUSIONS Cluster analysis of clinical variables identiﬁed 4 distinct phenotypes of chronic HF. Our ﬁndings
underscore the high degree of disease heterogeneity that exists within chronic HF patients and the need for improved
phenotyping of the syndrome. (Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart
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6MWD = 6-min walk distance
AF = atrial ﬁbrillation
COPD = chronic obstructive
pulmonary disease
CPET = cardiopulmonary
exercise testing
CRT = cardiac
resynchronization therapy
CV = cardiovascular
HF = heart failure
ICD = implantable
cardioverter-deﬁbrillators
LVEF = left ventricular
ejection fraction
NT-proBNP = N-terminal
pro-B-type natriuretic peptide
NYHA = New York Heart
Association
QOL = quality of life
VO2 = oxygen consumption
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1766C hronic heart failure (HF) is a syn-drome rather than a speciﬁc disease,with several subtypes that may
respond uniquely to therapeutic interventions
(1). However, despite advances in our under-
standing of HF pathogenesis, its classiﬁcation
continues to rely on imprecise measures that
may lead to overlapping diagnostic labels
and misclassiﬁcation (2,3). For example,
chronic HF is still clinically deﬁned along sub-
jective measures of functional status (New
York Heart Association [NYHA] functional
class), arbitrary left ventricular ejection frac-
tion (LVEF) cutpoints (HF with preserved vs.
reduced EF), or stages (A to D), despite the
increasing recognition that these constructs
provide inadequate phenotyping of the syn-
drome (4–6).SEE PAGE 1775Inadequately classifying patients within a
disease state like HF may produce severalpotentially important consequences. Because thera-
peutic interventions are frequently based on target-
ing certain patient subgroups, it may lead to
ineffective or inappropriate treatments. In fact, the
shortcomings in contemporary HF classiﬁcation have
been posited as a possible explanation for why we
have seen such little progress in developing new
treatments for this disorder (7,8). Improving the
“taxonomy” of clinical classiﬁcation may therefore
offer important clinical beneﬁts. Although molecular
phenotyping can theoretically provide more rational
disease descriptions, an essential ﬁrst step is to
identify disease subtypes on the basis of key clinical
variables, such that downstream biological measure-
ments can be appropriately anchored in patient-level
data. To address these issues, the National Research
Council has released a report that calls for a new
taxonomy of disease on the basis of both clinical and
molecular measures that will provide a more accurate
classiﬁcation of disease, with the ultimate goal of
enhancing diagnosis and treatment (9).
A widely used exploratory and hypothesis-
generating approach in biological studies, called clus-
tering, can play a role in identifying subtypes in
complex diseases. This approach has been extensively
used in analyzing molecular data across diseaseis. All other authors have reported that they have no relationshi
is manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
o listen to this issue’s audio summary by JACC Editor-in-Chief D
received March 7, 2014; revised manuscript received July 15, 20states, but it has seldom been used to examine clinical
variables. However, several reports have suggested
that clustering can lead to improved characteri-
zation of the disease phenotype (10,11). Accordingly,
we applied cluster analysis to examine the presence of
clinically important patient subgroups within a well-
characterized cohort of chronic systolic HF patients
who were randomized to exercise training versus
usual care. We also examined patterns of adverse
clinical outcomes among derived patient clusters and
interaction with randomized treatment assignment.
METHODS
STUDY POPULATION. Details of the design, rationale,
and primary results of the HF-ACTION (Heart Failure:
A Controlled Trial Investigating Outcomes of Exercise
Training) study have been published elsewhere
(12,13). Brieﬂy, HF-ACTION (NCT00047437) was a
randomized clinical trial that evaluated the effect of
exercise training versus usual care on long-term
morbidity and mortality in 2,331 patients with
chronic HF due to LV systolic dysfunction (NYHA
functional classes II to IV, LVEF #35%). Patients
were randomized to either usual HF care or a struc-
tured, group-based, supervised exercise program. All
patients, regardless of treatment group, received
detailed self-management educational materials that
included information on medications, ﬂuid manage-
ment, symptom exacerbation, sodium intake, and
amount of activity recommended by American College
of Cardiology/American Heart Association guidelines
(14). Patients were followed for a median of 2.6 years.
ASSESSMENT OF CLINICAL VARIABLES AND
BIOMARKERS. At the baseline clinic visit before
randomization, demographic characteristics, socio-
economic status, medical history, current medica-
tions, a physical examination, and the most recent
laboratory tests were obtained. Participants reported
race and ethnicity at the time of study enrollment
using categories deﬁned by the National Institutes of
Health. All patients underwent baseline and 3-month
cardiopulmonary exercise testing (CPET), during
which key exercise parameters were ascertained. In
addition, a standard 6-min walk test (6MWD) was
performed in each patient during the baseline visit.
Transthoracic echocardiography (TTE) was performed
at baseline, and key measures were acquired by theps relevant to this paper to disclose.
ntin Fuster.
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1767core laboratory, including LVEF and mitral regurgi-
tation assessment. Health status measures were
ascertained using several validated psychometric in-
struments at baseline to measure health-related
quality of life (QOL), pain, depression, and social
support, including the Kansas City Cardiomyopathy
Questionnaire, and the Multidimensional Scale of
Perceived Social Support (15). Baseline biomarker
levels of N-terminal pro-B-type natriuretic peptide
(NT-proBNP), ST2, and galectin-3 were evaluated in a
subset of patients who agreed to participate in the
biomarker substudy, using previously described
methodologies (16,17).
CLINICAL ENDPOINTS. The primary endpoint of
HF-ACTION was a composite of all-cause mortality and
all-cause hospitalization over a median follow-up of
2.6 years. Additional endpoints of interest included the
change from baseline in peak oxygen consumption
(VO2) per unit of time at 3 months, all-cause mortality,
a composite endpoint of cardiovascular (CV) mortality
or CV hospitalization, and the composite endpoint of
CV mortality or HF hospitalization. An independent
clinical events committee adjudicated all deaths and
all ﬁrst hospitalizations.
STATISTICAL ANALYSIS. Cluster analysis deﬁnes the
distances between subjects on the basis of the com-
bined values of their measured characteristics. Using
a matrix of distance measurements, cluster analysis
ﬁnds groups of subjects who are more similar to each
other than in those in other groups (Online Figure 1).
It can be used to describe disease phenotypes without
the need for historical or arbitrary a priori assump-
tions about classiﬁcation.
Details of the statistical analysis performed are
included in the Online Appendix. Brieﬂy, we selected 45
candidate variables measured at baseline that repre-
sented key characteristics of patients with HF, including
demographic characteristics, medical history, labo-
ratory values, QOL scores, and exercise capabilities
(Online Table 1). As is necessary for cluster analysis,
patients with missing data for any variables were
excluded, resulting in an analytical population of 1,619
of 2,331 patients (70% of the baseline study population).
We performed a cluster analysis on these variables and
obtained 4 distinct clusters of chronic HF patients
(Online Figure 2). The association between cluster
membership and clinical outcomes was assessed using
Cox proportional hazards regression. We assessed pro-
portional hazards assumptions graphically by evaluating
the standardized score process and the supremum test,
and found no violations (18). Using interaction terms in
aCox regressionmodel,wealso assessedwhether cluster
membership was associated with a differential response
to randomized exercise therapy for each outcome.All analyses were performed with SAS version
9.2 (SAS Institute, Cary, North Carolina) and R 2.15.3
(R Development Core Team, Vienna, Austria). A
p value #0.05 was considered statistically signiﬁcant
for all analyses. All of the authors had full access to
the data and take full responsibility for data integrity.
RESULTS
Complete baseline data for the pre-speciﬁed 45 clinical
variables of interest were available for 1,619 of the 2,331
patients who participated in the HF-ACTION trial;
these patients were included in the study. The cluster
analysis identiﬁed 4 patient clusters. Clinical variables
according to cluster are shown in Table 1, and socio-
economic variables in Table 2. Table 3 contains objec-
tive measures of HF according to patient cluster.
Baseline characteristics of the overall population and
the subgroup used for the analysis were broadly
similar, and are shown in Online Table 2. Key charac-
teristics of each patient cluster were as follows.
CLUSTER 1 (n [ 773). This was the largest cluster
with >2 times more patients than the other clusters.
Patients tended to be older Caucasian men (age
>60 years) with a history of tobacco use, high rates of
ischemic cardiomyopathy (68%), and advanced NYHA
functional class (39% with class III or IV). Despite
having the second highest rates of coronary artery
bypass graft surgery and percutaneous coronary
intervention, they had the second lowest rates of
angina symptoms (11.3%), with only 1% with Canadian
Cardiovascular Society angina classes 2 to 4. They had
the highest rates of common comorbidities, such as
atrial ﬁbrillation (AF), renal insufﬁciency, and chronic
obstructive pulmonary disease (COPD), as well as use
of implantable cardioverter-deﬁbrillators (ICDs) and
coronary resynchronization therapy (CRT). Cluster 1
patients were most likely to be married, least likely to
be divorced, had the second highest rates of college
graduation and income, and were most likely to
either be employed or retired (63%). They had objec-
tive evidence of the most advanced disease—
lowest median peak VO2 levels (13.5 ml/kg/min),
highest ventilation versus carbon dioxide production
slope (34), and lowest 6MWD (351 m)—but they had
the second lowest rates of previous HF hospitaliza-
tion and the second highest QOL scores. They also
had the highest median levels of all of the 3 HF bio-
markers studied: NT-proBNP (1,079 pg/ml), galectin-3
(15.4 ng/ml), and ST2 (26.2 ng/ml).
CLUSTER 2 (n [ 287). These patients were, on
average, the youngest (median age 49 years). They
were the most likely to be African American (69%)
and had the second highest percent of women
TABLE 1 Baseline Clinical Characteristics According to Patient Clusters
Cluster 1
(n ¼ 773)
Cluster 2
(n ¼ 287)
Cluster 3
(n ¼ 313)
Cluster 4
(n ¼ 246) p Value*
Age, yrs 63 (56–72) 49 (40–56) 60 (53–68) 55 (46–64) <0.001
Female 21.0 38.0 25.0 39.0 <0.001
Black 28.0 69.0 28.0 20.0 <0.001
White 67.0 27.0 67.0 77.0 <0.001
BMI, kg/m2 30 (26–34) 34 (27–41) 29 (27–33) 28 (25–33) <0.001
Systolic BP, mm Hg 112 (102–126) 117 (108–130) 114 (102–130) 104 (94–114) <0.001
Diastolic BP, mm Hg 70 (62–78) 76 (68–84) 70 (60–80) 64 (60–72) <0.001
Ischemic cardiomyopathy 68.0 10.0 80.0 9.0 <0.001
Previous heart failure hospitalizations
None 76.8 56.1 74.4 81.3 <0.001
1 17.9 33.4 19.2 14.6
2 3.5 7.7 3.2 2.4
$3 1.8 2.8 3.2 1.6
Symptoms
NYHA functional classes III–IV 39.0 27.0 43.0 21.0 <0.001
History of angina 11.0 14.0 97.0 7.0 <0.001
CCS angina class
0 95.0 90.0 29.0 98.0 <0.001
1 4.0 8.0 28.0 2.0
2–4 1.0 2.0 43.0 0.0
Medical and surgical history
History of MI 55.2 6.6 70.9 6.1 <0.001
Hypertension 71.2 64.5 74.1 12.6 <0.001
Diabetes 41.9 21.6 41.2 5.7 <0.001
Atrial ﬁbrillation/ﬂutter 31.8 6.6 14.7 11.8 <0.001
Hyperlipidemia 76.8 40.8 83.7 38.6 <0.001
Stroke 12.0 12.5 9.9 4.1 0.003
PVD 9.7 4.2 6.7 0.8 <0.001
COPD 12.7 13.2 8.9 4.5 0.001
Previous valve surgery 8.0 1.0 3.2 4.9 <0.001
Previous PCI 27.8 3.1 42.8 2.8 <0.001
Previous CABG 37.1 1.7 42.2 1.6 <0.001
Laboratories
Sodium, mmol/l 139 (137–141) 139 (138–141) 139 (137–141) 139 (137–140) 0.033
Creatinine, mg/dl 1.3 (1.1–1.6) 1.1 (0.9–1.3) 1.2 (1.0–1.4) 1.1 (0.9–1.2) <0.001
Blood urea nitrogen, mg/dl 23 (17–32) 16 (12–20) 20 (15–26) 18 (14–24) <0.001
Medications and devices
ACE-I or ARB 93.4 94.8 93.3 97.2 0.140
Beta-blocker 95.0 95.8 95.2 93.9 0.787
Loop diuretic agent 81.0 81.9 78.0 69.5 <0.001
Digoxin 49.5 43.2 43.5 49.6 0.118
ICD 53.3 15.7 39.6 37.4 <0.001
CRT 25.2 4.5 14.7 19.1 <0.001
Resting ECG conduction
Normal 31.8 73.9 46.6 37.0
LBBB 14.9 8.7 16.3 26.4
RBBB 4.8 2.8 4.2 1.6 <0.001
IVCD 14.9 10.8 13.7 14.2
Paced 33.6 3.8 19.2 20.7
Values are median (interquartile range), or %. *p Values for the comparisons of variables across clusters.
ACE-I ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; BP ¼ blood pressure; CABG ¼ coronary artery bypass
grafting; CCS ¼ Canadian Cardiovascular Society; COPD ¼ chronic obstructive pulmonary disease; CRT ¼ cardiac resynchronization therapy; ECG ¼ electrocardiogram; HF ¼
heart failure; ICD ¼ implantable cardioverter-deﬁbrillator; IVCD¼ intraventricular conduction delay; LBBB ¼ left bundle branch block; MI ¼myocardial infarction; NYHA ¼ New
York Heart Association; PCI ¼ percutaneous coronary intervention; PVD ¼ peripheral vascular disease; RBBB ¼ right bundle branch block.
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TABLE 2 Baseline Psychosocial Characteristics According to Patient Clusters
Cluster 1
(n ¼ 773)
Cluster 2
(n ¼ 287)
Cluster 3
(n ¼ 313)
Cluster 4
(n ¼ 246) p Value*
Marital status
Married 64 38 63 60
Divorced 13 16 14 14 <0.001†
Single (never married) 7 25 8 13
Other 16 21 15 13
Smoking status
Never 31 44 32 59 <0.001
Current 14 28 13 9
Past 54 28 55 35
Alcohol use 43 43 46 43 0.864
Highest level of education
Less than high school 11 12 14 5
High school 28 32 29 25 0.004†
Associate degree 9 11 10 10
College 19 9 12 22
Graduate school 9 5 6 16
Other 24 31 29 22
Employment status
Employed full time 16 23 14 27
Employed part time 6 5 6 5
Disabled 27 44 38 28 <0.001†
Unemployed 4 13 4 7
Retired 47 11 34 28
Other 0 4 4 5
Income
<$15,000 17 27 24 13
$15,000–$24,999 16 18 17 17
$25,000–$34,999 13 14 16 12
$35,000–$49,999 16 13 15 11 <0.001†
$50,000–$74,999 15 10 14 19
$75,000–$99,999 8 4 6 8
>$100,000 6 3 4 12
Quality of life
KCCQ Score 72 (54–85) 63 (43–80) 60 (47–76) 76 (60–86) <0.001
BDI-II Score 8 (4–13) 10 (5–19) 10 (6–16) 7 (4–13) <0.001
Euro thermometer 70 (60–80) 66 (50–80) 65 (50–80) 70 (60–80) <0.001
Values are % or median (interquartile range). *p Values for comparisons across clusters. †p Values for the
dichotomized comparison of each variable as follows: income: <$25,000 versus $$25,000; education: <high
school versus $high school; marital status: positive current or previous partner (married, living with partner,
widowed) versus no partner (single, divorced, separated); employment status: employed, volunteer, student,
homemaker, or retired versus unemployed or disabled.
BDI-II ¼ Beck Depression Inventory-II; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire.
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1769(38.3% vs. 39% in cluster 4). Median body mass index
was the highest (34 kg/m2), and HF etiology was
overwhelmingly (>90%) due to nonischemic causes
despite high rates of risk factors for atherosclerotic
heart disease. Patients in this cluster had the highest
rates of previous cerebrovascular accident and COPD,
but they also had low rates of other comorbidities,
such as AF and peripheral vascular disease. They had
the lowest rates of ICD and CRT use (15.7% and 4.5%,
respectively), which was less than one-half of that in
the next lowest group (37.4% and 19.1%, respectively,
in cluster 4). Cluster 2 patients were the least likely to
be married or employed, and had the lowest levels of
education and income. They exhibited objective evi-
dence of less advanced HF; after cluster 4, they had
the second highest median peak VO2 levels (15.0
ml/kg/min) and 6MWD (351 m). They also had the
lowest median levels of NT-proBNP (418 pg/ml) and
galectin-3 (11.9 ng/ml), and ST2 levels were similar to
cluster 4 (21.2 ng/ml vs. 21.1 ng/ml). Despite this,
cluster 2 patients had the highest rates of previous
hospitalization and the second lowest QOL scores.
CLUSTER 3 (n [ 313). In terms of age, sex, and racial
makeup, these patients were similar to the overall HF-
ACTION study (means age 60 years, 64% Caucasian,
and 75% male). HF was primarily due to ischemic car-
diomyopathy (80%). The unique characteristic in
these patients appeared to be their high burden of
angina symptoms (97%; 43% in Canadian Cardiovas-
cular Society class III or IV vs. <2% for all other clus-
ters), and consistent with this, they had the highest
rates of prior percutaneous coronary intervention and
coronary artery bypass graft surgery. After cluster 1
patients, they had the second highest rates of ICD and
CRT use. Cluster 3 patients had the second lowest rates
of education, employment, and income. They dis-
played objective evidence of advanced HF, and had
the second lowest median peak VO2 levels (14.7 ml/kg/
min) and 6MWD (376 m). Consistent with this, they
had the second highest levels of all 3 prognostic bio-
markers (after cluster 1): NT-proBNP (775 pg/ml),
galectin-3 (14.5 ng/ml), and ST2 (23.5 ng/ml). They had
the second highest rates of previous hospitalizations,
and the lowest QOL scores.
CLUSTER 4 (n [ 246). This cluster included the
highest percent of Caucasians (77%) andwomen (39%),
with amedian age of 55 years. Themajority had HF due
to nonischemic causes (>90%), and they had consid-
erably lower rates of risk factors and comorbidities
than all other patients (except for AF, which was only
lower in cluster 2). Cluster 4 patients were the least
likely to have been smokers; they had the highest
levels of educational attainment and income, andwere
the most likely to be employed. These patients hadobjective evidence of themildest degree of HFwith the
highest median peak VO2 levels (17.5 ml/kg/min) and
6MWD (427 m). They also had the second lowest me-
dian levels of NT-proBNP and galectin-3 (after cluster
2). These patients had the lowest rates of previous
hospitalization and the highest QOL scores. At base-
line, 37.4% had an ICD, and they had the second
highest usage of CRT devices (19.1%).
CLINICAL OUTCOMES. Figure 1 shows the risk of pri-
mary and secondary clinical outcomes of the
HF-ACTION study for each cluster, with cluster 1
(highest risk) as the comparator group. Compared with
TABLE 3 Objective Predictors of Heart Failure Prognosis According to Patient Clusters
Patient Biomarkers
Cluster 1
(n ¼ 773)
Cluster 2
(n ¼ 287)
Cluster 3
(n ¼ 313)
Cluster 4
(n ¼ 246) p Value
LVEF, % 25 (20–30) 25 (20–30) 25 (20–30) 24 (19–30) 0.606
Peak VO2, ml/kg/min 13.5 (11.0–16.5) 15.0 (12.1–18.0) 14.7 (12.0–17.9) 17.5 (14.2–20.7) <0.001
VEVCO2 slope 34 (30–40) 30 (26–34) 33 (29–39) 31 (27–35) <0.001
6MWD, m 351 (290–416) 394 (320–439) 376 (305–441) 427 (363–476) <0.001
NT-proBNP, pg/ml (n ¼ 1,011) 1,079 (461–2,517) 418 (194–978) 775 (359–1,663) 558 (206–1,606) <0.001
Galectin-3, ng/ml (n ¼ 664) 15.4 (11.9–21.0) 11.9 (9.8–14.9) 14.5 (10.8–20.1) 12.3 (10.2–16.7) <0.001
ST2, ng/ml (n ¼ 677) 26.2 (20.5–35.1) 21.2 (15.7–28.3) 23.5 (19.0–30.5) 21.1 (16.3–26.7) <0.001
Values are median (interquartile range).
6MWD ¼ 6-min walking distance; LVEF ¼ left ventricular ejection fraction; NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide; VEVCO2 ¼ minute ventilation  carbon
dioxide production relationship; VO2 ¼ oxygen consumption per unit of time.
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1770cluster 1, risk of the composite endpoint of all-cause
mortality and/or all-cause hospitalization ranged
from 0.65 (95% conﬁdence interval [95% CI]: 0.54 to
0.78) for cluster 4 to an equivalent 1.02 (95% CI: 0.87 to
1.19) for cluster 3. When considering all-cause mor-
tality, cluster 3 patients demonstrated an almost 40%
lower risk of mortality (0.61 [95% CI: 0.44 to 0.86]),
but risk of other outcomes was similar, suggesting a
higher risk of hospitalization. Cluster 4 patients had
the best risk proﬁle, with 35% to 55% lower risk for
adverse outcomes compared with cluster 1.
Figure 2 shows Kaplan-Meier curves, according
to patient cluster, for the primary endpoint of all-
cause death or all-cause hospitalization, and the
secondary endpoint of all-cause mortality. As shown,
patients in clusters 1 and 3 were at the highest risk for
the primary outcome; patients in cluster 4 were at
the lowest risk. When considering all-cause death,
cluster 1 patients had the highest mortality rates,
suggesting that cluster 3 patients had high rates of
hospitalization.Cluster 2 vs 1 Cluster 3 vs 1 Cluster 4 vs 1
All-cause mortality or all-cause
hospitalization (primary endpoint)
Cardiovascular mortality or
cardiovascular hospitalization
Cardiovascular mortality or
heart failure hospitalization
All-cause mortality
P≤0.001
P≤0.001
P≤0.001
P≤0.001
0 0.2 0.4 0.6 0.8 1 1.2
FIGURE 1 Risk of Clinical Events Compared With Cluster 1
(Highest Risk)*
*Symbols represent hazard ratios and 95% conﬁdence intervals.I NTERACT ION WITH EXERC ISE TRA IN ING
INTERVENT ION . Beneﬁts from exercise training,
the randomized intervention tested in HF-ACTION,
varied across patient clusters (Central Illustration).
We found evidence of signiﬁcant improvements in
3-month peak VO2 levels with exercise training in
cluster 2 and 3 patients (1.33 [95% CI: 0.67 to 1.98]
ml/min and 0.87 [95% CI: 0.24 to 1.51] ml/min,
respectively; p for interaction ¼ 0.04). Signiﬁcant dif-
ferences were also seen in the impact of exercise
training on 2 clinical outcomes (CV death and/or CV
hospitalization; p for interaction ¼ 0.0396, and CV
death and/or HF hospitalization; p for interaction ¼
0.0316). Clusters 1 and 2 appeared to have 12% to 30%
risk reduction from exercise training, whereas cluster
4 had an indication for increased harm (50% to 62%);
however, the conﬁdence intervals were wide and
included 1 in all cases, except for the endpoint of CV
death and/or CV hospitalization.
DISCUSSION
We applied a novel approach to a robust database
from a recent, large, randomized, controlled trial of
exercise training to identify 4 clinically relevant
phenotypes of chronic systolic HF. Patients within
each cluster varied considerably among the measures
of age, sex, race, symptoms, comorbidities, HF etiol-
ogy, socioeconomic status, QOL, CPET parameters,
and biomarker levels. We noted differential associa-
tions with risk of hospitalization and mortality be-
tween and within clusters, as well as varied responses
to exercise therapy (Central Illustration). These ﬁnd-
ings underscore the signiﬁcant heterogeneity that
exists within chronic HF patients and the need for
improved syndrome phenotyping.
To our knowledge, this is the ﬁrst application of
cluster analysis to identify distinct clinical pheno-
types in a large cohort of patients with chronic HF,
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Hospitalization and to All-Cause Mortality
Kaplan-Meier curves, according to patient cluster, that depict
(A) the primary endpoint of death or hospitalization (from any
cause), and (B) the secondary endpoint of death from any cause.
CENTRAL ILLUSTRATION Consort Diagram Showing Cluster Methodology Applied
to the HF-ACTION Study and the 4 Distinct Clusters That Emerge
Interaction between exercise therapy and patient clusters extracted from the study.
Symbols represent hazard ratios (HR) and 95% conﬁdence intervals, with HR <1.00
denoting beneﬁt from exercise, and HR >1.00 denoting harm. BMI ¼ body mass index;
CMP ¼ cardiomyopathy; CPET ¼ cardiopulmonary exercise testing; HF ¼ heart failure;
QOL ¼ quality of life; SES ¼ socioeconomic status.
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1771a syndrome believed to comprise multiple disease
subtypes (3). Several previous studies have used
this method to identify clinically relevant patient
subgroups within similarly complex, yet disparate
syndromes, such as COPD, Parkinson’s disease, and
human encephalitis, leading to new insights about
disease pathophysiology (19–22). In general, the
impact of these studies was limited by their small
size, low number of available clinical variables, a
well-phenotyped population, and lack of outcome
data. The HF-ACTION database was ideal to overcome
these limitations.
The ﬁndings presented here are important for
several reasons, especially when considering that
measurement of the LVEF—the methodology most
commonly used to describe HF—was 1 of only a handful
of variables that was statistically identical across all
4 patient clusters; this emphasizes the need for
improved descriptions of HF subtypes. We identiﬁed
2 clusters of patients with HF as a result of ische-
mic cardiomyopathy (clusters 1 and 3) that differed
dramatically in frequency and intensity of anginasymptoms (prevalence: 11% vs. 97%; Canadian Cardi-
ology Society angina classes II to IV: 1% vs. 43%).
Consequently, despite having objective measures of
milder disease and far higher rates of revascularization
procedures, patients in cluster 3 had greater risk of
hospitalization and the poorest QOL. Previous studies
have noted the persistence of anginal symptoms in HF
patients despite revascularization, suggesting that
pain mechanisms in this patient population might not
entirely be ameliorated by restoring epicardial blood
ﬂow (23). Despite higher rates of rehospitalization, the
mortality rates for cluster 3 patients were 40% lower
than cluster 1 patients. This suggests that novel stra-
tegies to improve angina symptoms in this patient
subtype might be clinically impactful (24).
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1772We also identiﬁed a cluster of patients who tended
to be young, obese African Americans with non-
ischemic cardiomyopathy. Despite objective evidence
of milder disease on the basis of CPET parameters
and HF biomarkers, these patients had high rates
of hospitalization and low QOL scores, which
conﬁrmed previous pre-speciﬁed analyses in this
patient population (25). These patients also exhibited
the lowest rates of ICD use (15.7%), although
almost all qualiﬁed on the basis of EF and NYHA
criteria. Whether socioeconomic factors caused these
differences is unknown, although racial and socio-
economic differences in medical device use have been
noted previously (26). Furthermore, the etiology of HF
in these patients was unclear; whether it resulted
from hypertension or other known causes, or it rep-
resented a distinct pathophysiological entity, is an
intriguing notion that requires further study (27).
Cluster 2 patients also possessed surprisingly low
rates of conduction abnormalities and the lowest
levels of biomarkers that elevate in response to
myocardial stretch and ﬁbrosis. This might explain the
distinct natural history of HF previously noted in this
patient population, and potentially, differential re-
sponses to therapeutics (28–30). Lastly, it appears that
the highest rates of rehospitalization in these patients
occurred despite objective measures of milder HF; this
might suggest that therapies aimed at improving dis-
ease state alone would not decrease rehospitalization
rates. Rather, a focused effort at understanding the
global reasons for rehospitalization might result in
more effective prevention strategies (31,32).
The fourth cluster mostly included Caucasian pa-
tients with the highest percent of women (39%) and
the highest socioeconomic status, as well as the
mildest form of HF from nonischemic cardio-
myopathy. These patients had the lowest rates
of comorbidities, objective measures that signiﬁed
the most cardiopulmonary reserve, and highest
QOL scores. Intriguingly, exercise therapy appeared
to be associated with worse outcomes in these
patients. Although highly speculative because of
the sample size, this might suggest that universal
recommendations for HF patients might not always
be beneﬁcial for lower risk patients.
Beyond what has been previously discussed, these
data carry important implications for patient care.
Although guidelines recommend treatment of all HF
patients according to disease severity and using
measures that might not capture disease heteroge-
neity, our ﬁndings imply that it may be important to
tailor therapeutics according to disease subtype on
the basis of a comprehensive evaluation of readily
available clinical data. Patients who resemble those incluster 1, for example, may beneﬁt from management
of their numerous comorbid conditions along with
HF, whereas patients similar to those in cluster 3
could beneﬁt from a focus on minimizing angina
symptoms. Furthermore, the increased use of elec-
tronic medical records may soon allow us to use
clustering algorithms on large amounts of clinical
data to improve phenotyping of patients, present
actionable information to medical practitioners, and
ultimately improve quality of care (33).
Our ﬁndings also shed light on the shortcomings of
clinical trials in patients with HF: a mechanistically
sound therapeutic intervention might not show efﬁ-
cacy when tested on a disease state with large pheno-
typic variations in etiology, clinical features, and
natural history (7,34). It has even been suggested that a
percent of patients in large clinical trials of HF might
not even have HF; this issue, therefore, might explain
the high number of negative results reported in large
trials of promising interventions for HF (35).
STUDY LIMITATIONS. Several limitations of this
analysis require consideration. First and foremost,
the present study was not meant to propose a new
classiﬁcation for chronic systolic HF, because the
clusters are likely to vary according to patient charac-
teristics and available data. These results serve to
underscore the need for novel multidimensional HF
classiﬁcation approaches for improving patient care
and trial quality. Furthermore, they are aimed to
generate hypotheses for future studies that will
integrate clinical and biological data in patients with
the goal of improving HF phenotyping. Second, pa-
tients with incomplete datasets were excluded from
cluster analyses, which necessitates complete data
on individual patients. Third, the patient population
represented those who participated in the HF-ACTION
clinical trial and might not generalizable to the entire
population of chronic HF patients. Fourth, the clus-
tering algorithm yielded results on the basis of the
available clinical variables, and the results might
have differed with more complete and accurate data.
Fifth, the choice of stopping the clustering algorithm
at 4 clusters included investigator discretion and
preference; a larger number of clusters might reﬁne
cluster descriptions, but smaller sizes might have
limited our ability to explore relationships with
clinical outcomes. In summary, we considered this
analysis to be hypothesis-generating; further studies
will be required to address these hypotheses.
CONCLUSIONS
We demonstrated that using a clustering algorithm on
the baseline clinical data of chronic HF patients can
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: There is
considerable heterogeneity among patients with chronic HF
related to etiology, clinical manifestations, and natural history;
certain characteristics identiﬁed by cluster analysis are associ-
ated with differences in outcomes.
COMPETENCY IN PATIENT CARE: In managing patients with
chronic HF, therapy should be individualized on the basis of
recognition of heterogeneity in key clinical characteristics.
TRANSLATIONAL OUTLOOK: Clinical trials could evaluate
responses to speciﬁc therapeutic interventions in subgroups of
patients with chronic HF who are distinguished by cluster analysis.
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1773identify 4 phenotypically distinct and clinically
meaningful groups. Patients within each cluster
varied considerably among the measures of age,
sex, race, symptoms, comorbidities, HF etiology,
socioeconomic status, QOL, CPET parameters, and
biomarker levels. We also demonstrated that patients
in each cluster responded distinctively to randomized
intervention assignment—in this case, exercise ther-
apy. These ﬁndings highlight the signiﬁcant het-
erogeneity that exists within chronic HF patients and
the need for improved phenotyping of the syndrome
to enhance therapeutic efﬁcacy.
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